Non-melanoma Skin Cancer Treated by Contact High-dose-rate Radiotherapy (Brachytherapy): A Mono-institutional Series and Literature Review.
Non-melanoma skin cancer
brachytherapy
radiation therapy.
radiotherapy
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
19
04
2021
revised:
11
05
2021
accepted:
21
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
1
7
2021
Statut:
ppublish
Résumé
Non-melanoma skin cancers (NMSC) are the most common neoplasms worldwide and their incidence has been proven to increase in recent years and their treatment should aim at cancer cure as well as cosmetic and functional results. The aim of the study was to report the results of our mono-institutional series of high-dose-rate radiotherapy (cHDR-RT) in NMSC, based on a homogenous technique and two different treatment schedules. All patients affected by NMSC who were consecutively evaluated and treated at our Interventional Oncology Center from October 2018 to August 2020, were included. Patients underwent cHDR-RT using flap applicators and remotely afterloaded Ir-192 sources. Overall, 51 patients were treated for a total of 67 lesions. Local control (LC) and disease-specific survival (DSS) were 94.0% and 100%, respectively. Grade 1, grade 2, grade 3 and grade 4 acute toxicity rates were 24.6%, 3.5%, 3.5%, and 0.0%, respectively. The cosmetic results were graded as excellent/good, fair, and poor in 73.7%, 19.3%, and 7.0%. cHDR-RT of NMSC is an effective alternative to surgery due to excellent outcomes both in terms of local control and aesthetic results especially in the face.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Non-melanoma skin cancers (NMSC) are the most common neoplasms worldwide and their incidence has been proven to increase in recent years and their treatment should aim at cancer cure as well as cosmetic and functional results. The aim of the study was to report the results of our mono-institutional series of high-dose-rate radiotherapy (cHDR-RT) in NMSC, based on a homogenous technique and two different treatment schedules.
PATIENTS AND METHODS
METHODS
All patients affected by NMSC who were consecutively evaluated and treated at our Interventional Oncology Center from October 2018 to August 2020, were included. Patients underwent cHDR-RT using flap applicators and remotely afterloaded Ir-192 sources.
RESULTS
RESULTS
Overall, 51 patients were treated for a total of 67 lesions. Local control (LC) and disease-specific survival (DSS) were 94.0% and 100%, respectively. Grade 1, grade 2, grade 3 and grade 4 acute toxicity rates were 24.6%, 3.5%, 3.5%, and 0.0%, respectively. The cosmetic results were graded as excellent/good, fair, and poor in 73.7%, 19.3%, and 7.0%.
CONCLUSION
CONCLUSIONS
cHDR-RT of NMSC is an effective alternative to surgery due to excellent outcomes both in terms of local control and aesthetic results especially in the face.
Identifiants
pubmed: 34182511
pii: 35/4/2313
doi: 10.21873/invivo.12505
pmc: PMC8286496
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2313-2319Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Nat Rev Clin Oncol. 2013 Jan;10(1):27-40
pubmed: 23165123
Adv Radiat Oncol. 2021 Mar-Apr;6(2):100605
pubmed: 33723523
J Contemp Brachytherapy. 2018 Jun;10(3):254-259
pubmed: 30038646
J Contemp Brachytherapy. 2015 Dec;7(6):497-502
pubmed: 26816508
Cureus. 2019 Dec 18;11(12):e6412
pubmed: 31988814
Head Neck. 2019 Jun;41(6):1667-1675
pubmed: 30701614
Pract Radiat Oncol. 2014 Nov-Dec;4(6):398-403
pubmed: 25407861
J Natl Compr Canc Netw. 2016 May;14(5):574-97
pubmed: 27160235
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):753-7
pubmed: 15927410
J Contemp Brachytherapy. 2017 Dec;9(6):497-498
pubmed: 29441092
Cancer Invest. 2015 Mar;33(2):34-8
pubmed: 25608635
J Am Acad Dermatol. 2011 Aug;65(2):377-388
pubmed: 21496952
Brachytherapy. 2015 Nov-Dec;14(6):840-58
pubmed: 26319367
Anticancer Res. 2021 Jan;41(1):1-7
pubmed: 33419794
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1136-1139
pubmed: 32333832
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
J Contemp Brachytherapy. 2020 Apr;12(2):105-110
pubmed: 32395133
Brachytherapy. 2018 May - Jun;17(3):601-608
pubmed: 29398593
Med Phys. 2014 Feb;41(2):021703
pubmed: 24506594
Pract Radiat Oncol. 2020 Jan - Feb;10(1):8-20
pubmed: 31831330
J Dermatolog Treat. 2018 Mar;29(2):170-175
pubmed: 28604229
J Geriatr Oncol. 2019 May;10(3):514-517
pubmed: 30314955
J Contemp Brachytherapy. 2020 Aug;12(4):406-411
pubmed: 33293981
J Contemp Brachytherapy. 2020 Feb;12(1):84-89
pubmed: 32190074
Radiother Oncol. 2018 Mar;126(3):377-385
pubmed: 29455924
Eur J Cancer. 2019 Sep;118:10-34
pubmed: 31288208
Brachytherapy. 2016 Sep-Oct;15(5):650-60
pubmed: 27263059
J Med Imaging Radiat Oncol. 2013 Apr;57(2):212-7
pubmed: 23551783
J Contemp Brachytherapy. 2018 Apr;10(2):115-122
pubmed: 29789760
Cancer Radiother. 2016 Jul;20(5):341-6
pubmed: 27321412
CA Cancer J Clin. 2019 Sep;69(5):386-401
pubmed: 31361333
Brachytherapy. 2017 Jan - Feb;16(1):223-229
pubmed: 27908679
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
Med Phys. 2020 Oct;47(10):e951-e987
pubmed: 32862452
J Contemp Brachytherapy. 2019 Oct;11(5):443-448
pubmed: 31749853
J Contemp Brachytherapy. 2016 Dec;8(6):533-540
pubmed: 28115960
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):95-102
pubmed: 10758310
Int J Mol Sci. 2020 Jul 29;21(15):
pubmed: 32751327
Eur J Dermatol. 2019 Aug 1;29(4):417-421
pubmed: 31486400
Tumori. 2017 Nov 23;103(6):516-524
pubmed: 28291904